The Diagnostic Usefulness of HMGA2, Survivin, CEACAM6, and SFN/14-3-3 δ in Follicular Thyroid Carcinoma

다국어 초록 (Multilingual Abstract)

Background: Follicular thyroid carcinoma (FTC) is the second most common thyroid malignancy and its differential diagnosis includes follicular adenoma (FA) and adenomatous goiter (AG). Several ancillary markers have been suggested to aid in the diagnosis of FTC, but the successful use of these methods still needs to be validated. Methods: In the present study, we verified the immunoexpression of HMGA2, CEACAM6, survivin, and SFN/14-3-3 δ in lesions including 41 AGs, 72 FAs, and 79 FTCs. We evaluated their diagnostic usefulness, combined with galectin 3, Hector Battifora mesothelial 1 (HBME1), cytokeratin 19, and cyclin D1, in diagnosing FTC. Results: The expressions of HBME1 (65.8%) and HMGA2 (55.7%) were significantly higher in FTCs than in FAs and AGs (p<.001 and p=.005, respectively). HBME1 was the only marker that was more frequently expressed in FTCs than in FAs (p=.021) and it was more frequently expressed in follicular neoplasms than in AGs (p<.001). Among the novel markers, the combination of HMGA2 and HBME1 showed the highest sensitivity (72.2%) and specificity (76.1%) for diagnosing FTC. CEACAM6, survivin, and SFN/14-3-3 δ were barely expressed in most cases. Conclusions: Our present results show that only HMGA2 can be beneficial in differentiating FTC using the novel markers.

참고문헌 (Reference)

1 Saleh HA, "Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules" 5 : 9-, 2010

2 de Matos PS, "Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy" 47 : 391-401, 2005

3 Belge G, "Upregulation of HMGA2 in thyroid carcinomas : a novel molecular marker to distinguish between benign and malignant follicular neoplasias" 47 : 56-63, 2008

4 Prasad NB, "Three-gene molecular diagnostic model for thyroid cancer" 22 : 275-284, 2012

5 Sigstad E, "The new molecular markers DDIT3, STT3A, ARG2 and FAM129A are not useful in diagnosing thyroid follicular tumors" 25 : 537-547, 2012

6 Lal G, "Regulation of 14-3-3sigma expression in human thyroid carcinoma is epigenetically regulated by aberrant cytosine methylation" 267 : 165-174, 2008

7 Baloch ZW, "Our approach to follicular-patterned lesions of the thyroid" 60 : 244-250, 2007

8 Mazzaferri EL, "Management of a solitary thyroid nodule" 328 : 553-559, 1993

9 Bryson PC, "Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas" 134 : 581-586, 2008

10 Haghpanah V, "Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma" 14 : 422-425, 2006

11 Prasad NB, "Identification of genes differentially expressed in benign versus malignant thyroid tumors" 14 : 3327-3337, 2008

12 Wiseman SM, "Hemithyroidectomy : the optimal initial surgical approach for individuals undergoing surgery for a cytological diagnosis of follicular neoplasm" 13 : 425-432, 2006

13 Chiappetta G, "HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias" 44 : 1015-1021, 2008

14 Prasad ML, "Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors" 18 : 48-57, 2005

15 Papale F, "Galectin-3 expression in thyroid fine needle cytology (t-FNAC) uncertain cases: validation of molecular markers and technology innovation" 228 : 968-974, 2013

16 LiVolsi VA, "Follicular-patterned tumors of the thyroid: the battle of benign vs. malignant vs. so-called uncertain" 22 : 184-189, 2011

17 Sobrinho-Simões M, "Follicular thyroid carcinoma" 24 (24): S10-S18, 2011

18 Kapur U, "Follicular neoplasm of the thyroid: vanishing cytologic diagnosis?" 35 : 525-528, 2007

19 McHenry CR, "Follicular adenoma and carcinoma of the thyroid gland" 16 : 585-593, 2011

20 박영주, "Diagnostic Value of Galectin-3, HBME-1, Cytokeratin 19, HighMolecular Weight Cytokeratin, Cyclin D1 and p27kip1 in the DifferentialDiagnosis of Thyroid Nodules" 대한의학회 22 (22): 621-628, 2007

21 Cerutti JM, "Diagnosis of suspicious thyroid nodules using four protein biomarkers" 12 (12): 3311-3318, 2006

22 김영아, "Detection of Survivin and COX-2 in Thyroid Carcinoma: Anaplastic Carcinoma Shows Overexpression of Nuclear Survivin and Low COX-2 Expression" 대한병리학회 46 (46): 55-60, 2012

23 Paunovic I, "Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19and HBME-1 in differential diagnosis of thyroid tumors" 120 : 368-379, 2012

24 Cerutti JM, "A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression" 113 : 1234-1242, 2004